Virlaza
Cerebremed
Forschung
DE
Forschung
LABPEI - Hot News | Virlaza™ inhibit cytokines release from airway epithelial cells in vitro
LABPEI - Hot news | Virlaza™ improves pulmonary, hematological and muscular recovery of post-covid-19 patient
22 July 2021
medRxiv | Virlaza™ Inhibits Sars-COV-2-induced Inflammatory Response of Bronchial Epithelial Cells and Pulmonary Fibroblast

17 July 2021
The ScienceGate | Virlaza Inhibits Sars-COV-2-induced Inflammatory Response of Bronchial Epithelial Cells and Pulmonary Fibroblast
4 June 2021
A Case Report | Virlaza™ Improves Cardiopulmonary Recovery of Post-Covid-19 Patient
11 February 2021
Report Virlaza™ in the Context of Lung Inflammation and Fibrosis in COVID-19
Virlaza
Cerebremed
Entwicklung und Forschung der Firma "LibiPharm" - "LibiPharm" Israel.
Datenschutzrichtlinie
© 2024 Calpton SIA. Alle Rechte vorbehalten.
Wir akzeptieren
Unsere AGB
Kontakte